NEP-GROUP
16.2.2024 09:16:29 CET | Business Wire | Press release
NEP Group, the leading worldwide media technology partner for live sports and entertainment, announced today that Lise Heidal has been appointed President, NEP Europe for NEP Broadcast Services, effective 1 April. Based in Norway, Heidal will set the strategy, priorities and focus areas for nine countries in Northern, Central and Southern Europe, as well as in the UK and Ireland, to lead the future planning of NEP’s broadcast services businesses.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240216806377/en/
Industry veteran Lise Heidal has been appointed President, NEP Europe for NEP Broadcast Services. She will set the strategy, priorities and focus areas for all countries in Northern, Central and Southern Europe, as well as in the UK and Ireland, to lead the future planning of NEP’s broadcast services businesses. (Photo: Business Wire)
With over 25 years of multifaceted experience in the media, telecom, and consulting industries, Heidal stands out as a pragmatic leader committed to driving operational excellence, business transformation and strategic innovation. Known as someone committed to building great teams with a genuine interest in the people she works with, Heidal’s approach combines strategic vision and operational expertise, whilst fostering a culture of accountability. Most recently she served 2,5 years as the VP of Production at TV 2, the largest commercial broadcaster in Norway. Prior to that, she served as Managing Director of NEP Norway and led several global NEP initiatives that achieved continuous development and profitable growth from 2010 to 2021.
As part of the new European leadership team, Christer Pålsson has been named Chief Commercial Officer for Europe, reporting into Heidal. As CCO, Pålsson will be responsible for all commercial and sales activities across the region and work closely with NEP’s global sales team to align strategy and execution, including for major events worldwide. He brings with him extensive experience in business leadership, sales, client service, partnerships and operations for NEP in the Nordics, Central and Southern Europe. Prior to joining NEP, Pålsson was Head of International Sales for Mediatec Broadcasting company, which became a part of NEP in 2015.
To support this transition NEP is also pleased to announce that Jose (Tex) Teixeira will join NEP on 4 April initially as President for NEP Nordics, Central & Southern Europe. Teixeira brings with him over 30 years of sport broadcast experience delivering world-class live productions in Africa and New Zealand. A creative, loyal and energetic individual with a can-do spirit, he has specialised in content strategy and acquisition, programming and production, leading large teams, building dynamic environments and managing strategic relationships with rights holders, federations and suppliers across multiple territories throughout his career. He most recently served as Chief Content Officer for SuperSport and as their Interim CEO in 2023.
Rounding out the European senior leadership team, Arjan van Westerloo and Steve Jenkins will continue in their current roles as President, NEP The Netherlands, and President, NEP UK & Ireland, respectively.
Mike Werteen, Global President of NEP Broadcast Services, said: “Combining our UK and European businesses under a single, dynamic and experienced leadership team is an exciting step forward. Having such a powerful group in place enables us to achieve our vision to be the leading global media services provider in live sports and entertainment. Under Lise’s direction, supported by the foundations that all European and UK team members have put into place, I’m confident we will be able to harness all of the talent, synergies, sales and employee career opportunities across these important markets.”
Lise Heidal said: "I am deeply honored to accept the position as lead of the NEP Broadcast Services European organization. It is a privilege to have the opportunity to work with a team of such dedicated and talented individuals. I am fully committed to enhancing our collaborative efforts across Europe, to serving our clients, and to continue building on our shared successes."
While continuing to manage the day-to-day business, the first priority for the European leadership team will be to drive increased collaboration and process improvements for the region as part of the company’s 2024 goals and longer-term plans.
For more information about NEP, visit www.nepgroup.com.
About NEP
You have a vision. We see it, too. With a worldwide network of experts and cutting-edge technology, our unique Global Production Ecosystem empowers content creators and rights holders to tell stories in breakthrough ways. We're built on 35 years of trusted experience across broadcast, live event, and virtual production to deliver the solutions you need—anytime, anywhere.
Headquartered in the United States, NEP has operations in 25 countries with over 5,000 employees. Together, we have supported productions in over 100 countries on all seven continents, and we’re still growing. Learn how we help our clients bring content to life at nepgroup.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240216806377/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
